Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Title Slide Strategic Center for Clinical Cancer Research Clinical Cancer Research using Emerging Advanced Technologies for Health Breast Cancer Mortality in Women, 1951-2000 Strategic Center for Clinical Cancer Research Lancet: 365,1727,2005 The CREATE Health team Strategic Center for Clinical Cancer Research Nano technology Proteomics Clinical Oncology Tumour biology Bioinformatics Genomics Proteomics Organisation Scientific Secretary CREATE Health Board Representatives from Lund University and Industry Strategic Center for Clinical Cancer Research Director Carl Borrebaeck Deputy Carsten Rose Steering Committee Financial Officer Scientific Advisory Board IPR Review board Administration Bioinformatics C Peterson DNA/RNA arrays Å Borg RNA/protein arrays C Borrebaeck Proteomics P James Nanotechnology T Laurell Clinical Oncology C Rose Tumor cell biology S Påhlman J Häkkinen J Vallon C Rovira S Ek C Wingren F Levander G Marko-Varga J Nilsson C Graffman M Ridderheim H Axelson C Larsson Localisation of BMC and USil Strategic Center for Clinical Cancer Research Localisation at the Biomedical Centre Strategic Center for Clinical Cancer Research You are here! Mission and Vision Statements Strategic Center for Clinical Cancer Research • To create an integrative approach to solve complex clinical problems, by developing novel techniques ”from bedside to bench and back again” • To create a substantial social impact for the patient through direct application of research for selection of an optimal, individually-based, cancer treatment Research and Development Strategic Center for Clinical Cancer Research Clinical focus To associate specific gene and/or protein signatures with: • Treatment-induced drug resistance • Treatment response & optimisation • Tumour relapse & survival time To identify novel targets for antibody-based therapy CREATE Health Work flow Strategic Center for Clinical Cancer Research Clinic CREATE Health Centre Sample handling Sample collection Sample storage & tracking Technology development & application Sample processning Sample analysis Technology development Investigators: Carl Borrebaeck Åke Borg Peter James Thomas Laurell Carsten Peterson Sven Påhlman Carsten Rose Clinic Data analysis & mining Clinical transfer Diagnostics/Treatment Diagnostic validation Treatment validation Benefits for the patients Strategic Center for Clinical Cancer Research Improved diagnosis • Increased analytical sensitivity and capacity Improved prediction of disease progression • Proteome-wide biomarker identification from fine needle/sure-cut biopsies Increased survival • Disease stratification and tailoring of therapy • Tumour specific antibodies for therapy Discovery Projects Strategic Center for Clinical Cancer Research Genomics focus • define gene defects that are hereditary • define chromosomal defects arising in cancer • develop pathway focused gene monitoring methods • find novel microRNA markers of cancer Proteomics focus • discover protein markers of disease in cancer cells • validate markers in serum for subsequent blood tests • develop peptide monitoring for plasma analysis Practical Application Projects Strategic Center for Clinical Cancer Research Antibody microarrays • antibody microarray based oncoproteomics • nanostructured high performance chips for fluorescence/MS • protein sampling in nanoscale for LCM single cell proteome Proteomic data basis & tools • BASE & Proteios integrated algorithms for breast & lymphomas • Cell reconstruction & validation Principle of Antibody Microarrays Strategic Center for Clinical Cancer Research Practical Example:Pancreatic Adenocarcinomas Strategic Center for Clinical Cancer Research Analysis of serum proteomes from 30 pancreatic carcinoma patients and 15 healthy individuals • red - upregulated • black - no change • green - down regulated 100% Sensitivity 100% Specificity Healthy Carcinoma Technology Transfer and Commercialisation Strategic Center for Clinical Cancer Research CREATE Health is actively engaged in developing its discoveries to benefit society and has a special board for IP issues. The CREATE Health team has generated > three worldwide patents/year over the past five years, ranging from basic research to applied biomedical inventions As a result, six spin-off firms have been created, some with > 100 employees. End Slide Strategic Center for Clinical Cancer Research www.createhealth.lth.se